Emory

Elypta anticipates launching a test to conduct surveillance for recurrence of renal cell carcinoma in patients that have undergone surgery.

The researchers said that their deep-learning interpreter of outcomes for patients with gliomas could be more accurate and objective than pathologists.

The British molecular diagnostics company plans to make its array-based test for early-stage Alzheimer's disease available in the US by year end.